Registry of Adjuvant Hormone-blockade Breast Cancer Patients Evaluated for Bone Mineral Metabolism

Recruiting now

Conditions studied: Breast Cancer

In brief

Establishment of a registry by which to census all patients treated with adjuvant hormone blockade for previous breast cancer in order to evaluate in future studies the trend of bone mass and its relationship to laboratoristic indices inherent in calcium metabolism, and the prevalence and incidence of fractures.

Key facts

Study ID

NCT06773533

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

3000

Starts

2021-12-18

Expected to finish

2039-12-31

Last updated by the study team

2025-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Patient undergoing adjuvant hormone blockade therapy (aromatase inhibitors, GnRH analogs, tamoxifen) for breast cancer referred by UO Oncology Zamagni
• Performed densitometry at UO Radiology Lovato and performed hematochemical tests inherent to mineral metabolism
• Informed consent obtained

You may not qualify if…

• none

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.